Arcellx, Inc. (ACLX)
| Market Cap | 1.48B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -94.57M |
| Shares Out | 45.51M |
| EPS (ttm) | -15.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,762 |
| Open | 33.50 |
| Previous Close | 32.60 |
| Day's Range | 32.28 - 33.11 |
| 52-Week Range | 6.04 - 35.16 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 38.08 (+16.49%) |
| Earnings Date | Mar 23, 2023 |
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid le... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ACLX stock is "Buy." The 12-month stock price forecast is $38.08, which is an increase of 16.49% from the latest price.
News
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies' previously announ...
Why Is Arcellx (ACLX) Stock Up 25% Today?
Investors of Arcellx (NASDAQ: ACLX) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it's teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ...
Gilead to co-develop Arcellx's multiple myeloma drug
Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical tria...
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress
-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%...
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop ...
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; ...
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress
-- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in...
Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition
-- ASH abstract contains previously presented data from June 2022 -- -- New clinical data from a recent data cut will be presented at ASH -- -- Company to host a live webcast event with an expert pane...
Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet
The mean of analysts' price targets for Arcellx, Inc. (ACLX) points to a 61.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an...
Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference
REDWOOD CITY, Calif. , Sept. 7, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results
-- Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additional shares -- -- Presented continue...
Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel
REDWOOD CITY, Calif. , June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares
REDWOOD CITY, Calif. , June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering
-- Public Offering of 7,000,000 Shares of Common Stock for Gross Proceeds of $112 Million -- REDWOOD City, Calif. , June 15, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company ...
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting
-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached CR/sCR -- -- 13 of 16 patients (81%) dosed...
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Cli...
Arcellx Appoints Michelle Gilson as Chief Financial Officer
FOSTER CITY, Calif. , May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients wit...
Arcellx Appoints Olivia Ware to Board of Directors
-- Replaces Lewis T. "Rusty" Williams, M.D.
Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results
-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory multiple myeloma (r/r MM) -- -- Management to host liv...
Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma
-- ARC-SparX is a novel CAR-T cell therapy treatment designed to allow for controllability and adaptability to potentially reduce toxicities associated with serious dose-limiting adverse events and ov...
Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
100% ORR; 75% CR/sCR; and evidence of durable clinical benefit in a population with poor prognostic features observed in the dose escalation cohorts with CART-ddBCMA FOSTER CITY, Calif. , May 9, 2022 ...
Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference
FOSTER CITY, Calif. , May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with...
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, June 5, 2022, at 7:00 PM CDT -- FOSTER CITY, Calif., April 27, 2022 /PRNewswire/ -...
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting
-- ACLX-002 completely regresses multiple cell line and patient-derived AML xenografts -- -- Company plans to initiate ACLX-002 Phase 1 clinical trial in AML/MDS in 2H'22 -- FOSTER CITY, Calif., April...
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
-- Completed upsized initial public offering of common stock, raising $142.3 million in gross proceeds including full exercise of underwriters' option to purchase additional shares -- -- Expanded comp...